Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EHRs Become A Stronger Research Tool Under Proposed Stage 2 Meaningful Use Rule

Executive Summary

Use of electronic health records to report data to disease registries, for both cancer and non-cancer conditions, becomes an optional objective for providers to demonstrate “meaningful use” of EHRs under CMS’ proposed stage 2 requirements. An objective to identify patients for potential research opportunities also carries over to the stage 2 proposal.

You may also be interested in...

Antibiotics Go Head-To-Head In PCORI-Funded Observational Study

Patient-Centered Outcomes Research Institute selected five drug-related research topics for funding, including a look at narrow- versus broad-spectrum antibiotics for acute respiratory tract infections in children, though all studies are observational. PCORI approved 52 CER projects in this third funding round, including many declined in the first round.

Surescripts’ Expansion Into Health Info Exchange Offers Research Potential

While facilitating research is not necessarily Surescripts’ main goal as it transitions its network infrastructure from an e-prescribing-related data exchange to enabling more health information exchange, SVP Miller says the network could play a role in helping research benefit from the growth in health information technology.

CMS Finalizes Stage 2 Standards For Electronic Health Records With Delayed Implementation

Agency gives eligible physicians and hospitals that started earning incentive payments for the meaningful use of electronic health records in 2011 an additional year, until 2014, to begin demonstrating that they are meeting the standards outlined in the recently finalized rule.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts